Released Mar 12, 2020, before the open
10-K filed Mar 12, 2020, 72 days after period end · 0001104659-20-032540
Q4 2019 · 10-K
Revenue$17.76M$17.76M derived−34.3% vs Q4 2018+24.6% vs Q3 2019
Net Income$291.00K$291.00K N/M vs Q4 2018N/M vs Q3 2019
EPS Diluted$0.02$0.02 N/M vs Q4 2018N/M vs Q3 2019
Operating Income$2,200,000N/M
Operating Cash Flowderived-$3,687,000N/M
Free Cash Flowderived-$3,715,000N/M
Margins · derived
Operating margin12.4%+26.0 pt vs Q4 2018
Net margin1.6%+21.8 pt vs Q4 2018
What the release said
The release
Same quarter
| Metric | Q4 2019 | Q4 2018 | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures |
|---|---|---|---|---|
| Revenue | $17.76M | $27.02M | $4.31M | $2.08M |
| Net Income | $291.00K | -$5.43M | -$13.31M | -$2.62M |
| EPS Diluted | $0.02 | -$0.40 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR